Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Hypogonadotropic hypogonadism (HH) can be sustained by organic or functional alterations of the hypothalamic-pituitary-testicular axis. Functional HH is related to systemic alterations, such as obesity or chronic inflammatory diseases, but could contribute to a negative course of the illness. For such situation, according to results obtained in infertile women, the administration of selective estrogen receptor modulators (SERMs) has been proposed in males too, with positive results on both metabolic and sexual function. This class of medications increases gonadotropin levels via antagonism to the estrogenic receptor; similar biological effects are also exerted by aromatase inhibitors (AIs), despite different mechanism of action. After a brief review of trials regarding SERMs and AIs use in male HH, we describe the structure and function of the androgen receptor (AR) as a basis for clinical research about compounds able to bind to AR, in order to obtain specific effects (SARMs). The tissue selectivity and different metabolic fate in comparison to testosterone can potentiate anabolic versus androgenic effects; therefore, they might be a valid alternative to testosterone replacement therapy avoiding the negative effects of testosterone (i.e., on prostate, liver, and hematopoiesis). Trials are still at an early phase of investigation and, at the moment, the application seems to be more useful for chronic disease with catabolic status while the validation as replacement for hypogonadism requires further studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the central nervous system, some SERMs, namely clomiphene citrate and tamoxifen, function as antagonists to the estrogen receptor, thereby, inhibiting the negative feedback of estrogen to the hypothalamus and pituitary gland. This results in increased endogenous gonadotropin levels which stimulate testosterone production [4,17,47].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, they require a functional HPG axis and cannot be used in men with organic hypogonadism [47].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Selective estrogen receptor modulators (SERMs) selectively modulate the estrogen receptor leading to variable effects in different tissues.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [47]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast to TRT, these drugs preserve fertility.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [47]
The cited source says what the claim attributes to it.
In the citing paper
“Unlike the SERMs clomiphene citrate and tamoxifen, AIs reduce estrogen levels [47].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [47]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 1×
“AR-activated genes comprise KLK3 that encode the prostate-specific antigen (PSA), KLK2, FKBP5, transmembrane protease serine 2 (TMPRSS2), and several other transcripts [39].”
BackgroundTestosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736 · cited 1×
“, obesity, metabolic syndrome, diabetes mellitus, and so on) have been suggested [3, 4].”
BackgroundMorishima, A., Grumbach, M. M., Simpson, E. R., Fisher, C., & Qin, K. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530621 · Cited by 1,416 · cited 1×
“Different studies support this view showing severe male osteoporosis in patients affected by mutations of the estrogen receptor or mutations of the aromatase [58, 59].”
BackgroundPharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · cited 1×
“In these conditions, hypogonadism is related to a progressive worsening of the disease, despite an adequate therapy (for instance, the failure of diet in obese men) [5], contributing to the evolution by an unfavourable vicious circle.”
BackgroundMolecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942 · cited 1×
“In human beings, the androgen receptor (MW 110 kDa; 919-920 amino acids) is encoded by the AR gene located on the long arm chromosome X at the locus Xq11- Xq12 [28, 29].”
BackgroundKhosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Tajar, A., Forti, G., O'Neill, T. W., Lee, D. M., Silman, A. J., Finn, J. D., Bartfai, G., Boonen, S., Casanueva, F. F., Giwercman, A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1796 · Cited by 604 · cited 1×
“Hypogonadotropic hypogonadism, also known as secondary hypogonadism, is the most common form of hypogonadism in adult and elderly man [1], related to an absolute or relative defective secretion of gonadotropin-releasing hormone (GnRH) by the hypothalamus and/or gonadotropin secretion by the pituitary gland.”
BackgroundPharmacology of anabolic steroids
Kicman, A. T. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.165 · Cited by 580 · cited 1×
“Some of these are obtained by modification of the steroid structure, but others are nonsteroidal; it is an old concept, the myotrophic/androgenic index [41] as a major tool to evaluate androgen potency.”
BackgroundLubahn, D. B., Joseph, D. R., Sar, M., Tan, J.-A., Higgs, H. N., Larson, R. E., French, F. S., & Wilson, E. M. (1988) · Molecular Endocrinology · doi:10.1210/mend-2-12-1265 · Cited by 570 · cited 1×
“In human beings, the androgen receptor (MW 110 kDa; 919-920 amino acids) is encoded by the AR gene located on the long arm chromosome X at the locus Xq11- Xq12 [28, 29].”
BackgroundEffect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531 · cited 1×
“-e aim to further ameliorate anabolic effects should be on the other hand preferentially pursued for the extended indications to SARM therapy, especially osteoporosis in elderly men [43, 44], glucocorticoid-induced osteoporosis [43], HIV sarcopenia and cancer cachexia [45], anaemia, and muscular dystrophies [42, 46].”
BackgroundAndrogens in Men — Uses and Abuses
Bagatell, C. J., & Bremner, W. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341107 · Cited by 464 · cited 1×
“-e aim to further ameliorate anabolic effects should be on the other hand preferentially pursued for the extended indications to SARM therapy, especially osteoporosis in elderly men [43, 44], glucocorticoid-induced osteoporosis [43], HIV sarcopenia and cancer cachexia [45], anaemia, and muscular dystrophies [42, 46].”
BackgroundZhou, Z. X. (1995) · Molecular Endocrinology · doi:10.1210/me.9.2.208 · Cited by 411 · cited 1×
“Additionally, at low circulating androgen levels, DHT binding to AR is favourite in respect to T [35].”
BackgroundThe role of estradiol in male reproductive function
Ramasamy, R., Schulster, M., & Bernie, A. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.173932 · Cited by 411
Dalton, J. T., Barnette, K. G., Bohl, C. E., Hancock, M. L., Rodriguez, D., Dodson, S. T., Morton, R. A., & Steiner, M. S. (2011) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-011-0034-6 · Cited by 403
ORWOLL, E. S., & KLEIN, R. F. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-87 · Cited by 335
Kimura, N., Mizokami, A., Oonuma, T., Sasano, H., & Nagura, H. (1993) · Journal of Histochemistry & Cytochemistry · doi:10.1177/41.5.8468448 · Cited by 298 · cited 1×
“AR is expressed in several reproductive (breast, testes, prostate, ovary, and endometrium) and nonreproductive tissues (hair follicles, bone, brain, liver, and cardiovascular) [32].”
BackgroundNegro-Vilar, A. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.10.3459 · Cited by 282 · cited 2×
“-e aim to further ameliorate anabolic effects should be on the other hand preferentially pursued for the extended indications to SARM therapy, especially osteoporosis in elderly men [43, 44], glucocorticoid-induced osteoporosis [43], HIV sarcopenia and cancer cachexia [45], anaemia, and muscular dystrophies [42, 46].”
BackgroundGrossmann, M., & Matsumoto, A. M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3580 · Cited by 246
Discovery of Nonsteroidal Androgens
Dalton, J. T., Mukherjee, A., Zhu, Z., Kirkovsky, L., & Miller, D. D. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8209 · Cited by 226 · cited 1×
“SARMs were first described and subsequently developed to facilitate selective tissue activation of the AR [40].”
BackgroundPathogenesis of Age-Related Bone Loss in Humans
Khosla, S. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls163 · Cited by 222 · cited 1×
“Various evidences suggested a dominant role of estrogen on bone resorption, whereas both estrogen and testosterone are involved inmaintaining bone formation [60].”
BackgroundCorona, G., Giagulli, V. A., Maseroli, E., Vignozzi, L., Aversa, A., Zitzmann, M., Saad, F., Mannucci, E., & Maggi, M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0262 · Cited by 217
Self-citationSelective androgen receptor modulators as function promoting therapies
Bhasin, S., & Jasuja, R. (2009) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32832a3d79 · Cited by 216 · cited 3×
“-ese interactions are specific for the muscle, and therefore could be a strategy to a further development of anabolic drugs [47, 55].”
BackgroundBarrett-Connor, E., Mueller, J. E., von Mühlen, D. G., Laughlin, G. A., Schneider, D. L., & Sartoris, D. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6327 · Cited by 216 · cited 1×
“It is widely accepted that patients with low levels of estradiol present bone metabolism disorders and increased risk of fractures [56, 57].”
BackgroundAndrogen Receptor Splice Variants Dimerize to Transactivate Target Genes
Xu, D., Zhan, Y., Qi, Y., Cao, B., Bai, S., Xu, W., Gambhir, S. S., Lee, P., Sartor, O., Flemington, E. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0381 · Cited by 189 · cited 1×
“Homodimerization of AR is mediated by the dimerization box located in the DBD region to achieve an intermolecular DBD-DBD link and N/C-terminal interactions through the FXXLF motif [38].”
BackgroundAndrogen insensitivity syndrome: a review
Batista, R. L., Costa, E. M. F., Rodrigues, A. D. S., Gomes, N. L., Faria, J. A., Nishi, M. Y., Arnhold, I. J. P., Domenice, S., & Mendonca, B. B. D. (2018) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000031 · Cited by 186 · cited 1×
“Some of them might lower its function leading to the androgen insensitivity syndrome [33]; they encompass pathologic conditions which occur with different clinical phenotypes: spinal and bulbar muscular atrophy and partial or complete androgen resistance (i.”
BackgroundChua, M. E., Escusa, K. G., Luna, S., Tapia, L. C., Dofitas, B., & Morales, M. (2013) · Andrology · doi:10.1111/j.2047-2927.2013.00107.x · Cited by 183 · cited 1×
“On the contrary, both SERMs and AIs maintain the fertility, avoiding the block of spermatogenesis, as TRT does [7, 8].”
BackgroundGenetic and Clinical Spectrum of Aromatase Deficiency in Infancy, Childhood and Adolescence
Belgorosky, A., Guercio, G., Pepe, C., Saraco, N., & Rivarola, M. A. (2009) · Hormone Research in Paediatrics · doi:10.1159/000249159 · Cited by 171 · cited 1×
“Different studies support this view showing severe male osteoporosis in patients affected by mutations of the estrogen receptor or mutations of the aromatase [58, 59].”
BackgroundBioavailable Estradiol May Be an Important Determinant of Osteoporosis in Men: The MINOS Study
Szulc, P. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.192 · Cited by 169
Guay, A. T., Bansal, S., & Heatley, G. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530597 · Cited by 162 · cited 1×
“At variance with these results, both a retrospective study evaluating 77 hypogonadal and infertile men treated with CC [23] and a double-blind placebo-controlled study involving 17 subjects did not show any improvement in sexual function during CC therapy [24].”
ResultBhasin, S., Storer, T. W., Asbel-Sethi, N., Kilbourne, A., Hays, R., Sinha-Hikim, I., Shen, R., Arver, S., & Beall, G. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5079 · Cited by 159 · cited 1×
“-e aim to further ameliorate anabolic effects should be on the other hand preferentially pursued for the extended indications to SARM therapy, especially osteoporosis in elderly men [43, 44], glucocorticoid-induced osteoporosis [43], HIV sarcopenia and cancer cachexia [45], anaemia, and muscular dystrophies [42, 46].”
BackgroundBasaria, S., Collins, L., Dillon, E. L., Orwoll, K., Storer, T. W., Miciek, R., Ulloor, J., Zhang, A., Eder, R., Zientek, H., et al. (2013) · The Journals of Gerontology: Series A · doi:10.1093/gerona/gls078 · Cited by 150
Effects of Aromatase Inhibition in Elderly Men with Low or Borderline-Low Serum Testosterone Levels
Leder, B. Z., Rohrer, J. L., Rubin, S. D., Gallo, J., & Longcope, C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031467 · Cited by 149 · cited 1×
“did not find any significant difference in ED assessed by the International Index of Erectile Function during anastrozole (1mg/day) therapy in a placebocontrolled study conducted in elderly men [25].”
MethodBurnett-Bowie, S.-A. M., McKay, E. A., Lee, H., & Leder, B. Z. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0739 · Cited by 146
Miner, J. N., Chang, W., Chapman, M. S., Finn, P. D., Hong, M. H., López, F. J., Marschke, K. B., Rosen, J., Schrader, W., Turner, R., et al. (2007) · Endocrinology · doi:10.1210/en.2006-0793 · Cited by 136
Singh, R., Bhasin, S., Braga, M., Artaza, J. N., Pervin, S., Taylor, W. E., Krishnan, V., Sinha, S. K., Rajavashisth, T. B., & Jasuja, R. (2009) · Endocrinology · doi:10.1210/en.2008-0858 · Cited by 132 · cited 1×
“-ese interactions are specific for the muscle, and therefore could be a strategy to a further development of anabolic drugs [47, 55].”
BackgroundMolecular chaperones throughout the life cycle of the androgen receptor
Prescott, J., & Coetzee, G. A. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.12.037 · Cited by 131 · cited 4×
“-e activated AR (i.e., active AR which binds with A or DHT) complex is translocated to the nucleus and dimerizes as a AR homodimer (AR-dimer) that acts as a transcriptional regulator activating the gene expression by binding to the specific sequence, the androgen response element (ARE), site in DNA [37].”
BackgroundInfluentialGuay, A. T., Jacobson, J., Perez, J. B., Hodge, M. B., & Velasquez, E. (2003) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900981 · Cited by 128 · cited 1×
“Conversely, few studies with inconclusive data have been carried out on CC and AIs effect on erectile dysfunction (ED) in men so far [22].”
BackgroundThe hinge region in androgen receptor control
Clinckemalie, L., Vanderschueren, D., Boonen, S., & Claessens, F. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.02.019 · Cited by 104 · cited 1×
“-e DBD and LBD regions are connected by a flexible hinge region (residues 628–669) [30], called nuclear localization signal (NLS), that is, a lysine rich sequence and is important for nuclear localization of the AR receptor and is also a major target site for posttranslational modifications such as acetylation, methyl…”
BackgroundHelo, S., Ellen, J., Mechlin, C., Feustel, P., Grossman, M., Ditkoff, E., & McCullough, A. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12944 · Cited by 102 · cited 1×
“Although both SERMs and AIs can raise gonadotropin levels, they induce a different pattern of circulating steroid levels, as suggested by an important difference in the serum T/17β oestradiol (E2) ratio, depending on the kind of drug employed [14].”
BackgroundLima, F. R., Baima Filho, J., Kochem, J., Pereira, R. M. R., & Yoshinari, N. (1997) · PubMed · Cited by 99
Consideration of breast cancer subtype in targeting the androgen receptor
Venema, C. M., Bense, R. D., Steenbruggen, T. G., Nienhuis, H. H., Qiu, S.-Q., van Kruchten, M., Brown, M. A., Tamimi, R. M., Hospers, G. A. P., Schroder, C. P., et al. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.005 · Cited by 96 · cited 1×
“Consequently, AR is suggested as a new marker and potential therapeutic target in the treatment of patients against breast cancer [34].”
BackgroundHamann, L. G., Mani, N. S., Davis, R. L., Wang, X., Marschke, K. B., & Jones, T. K. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9806648 · Cited by 87
Ramasamy, R., Scovell, J. M., Kovac, J. R., & Lipshultz, L. I. (2014) · Journal of Urology · doi:10.1016/j.juro.2014.03.089 · Cited by 84
Indirect androgen doping by oestrogen blockade in sports
Handelsman, D. J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.150 · Cited by 84 · cited 1×
“Due to their activity, SERMs and AIs are also considered as indirect androgen doping due to their ability to increase T, being thus prohibited both in amateur and professional athletes [9].”
BackgroundGoudriaan, A. E., Lapauw, B., Ruige, J. B., Feyen, E., Kaufman, J., Brand, M., & Vingerhoets, G. (2010) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.04.005 · Cited by 83 · cited 1×
“5mg/day) therapy, positive behavioural effects can be observed (fear and risk taking) in healthy adult men [16].”
BackgroundMini-review: Foldosome regulation of androgen receptor action in prostate cancer
Cano, L. Q., Lavery, D. N., & Bevan, C. L. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.01.023 · Cited by 81 · cited 1×
“Due to the binding of androgens to AR, it undergoes a conformational change which leads to the dissociation of HSP and other proteins from the inactive AR that is converted in the active form [36].”
BackgroundEdwards, J. P., West, S. J., Pooley, C. L. F., Marschke, K. B., Farmer, L. J., & Jones, T. K. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00107-3 · Cited by 79
Wang, Q., Lu, J., & Yong, E. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009916200 · Cited by 75 · cited 1×
“-e DBD and LBD regions are connected by a flexible hinge region (residues 628–669) [30], called nuclear localization signal (NLS), that is, a lysine rich sequence and is important for nuclear localization of the AR receptor and is also a major target site for posttranslational modifications such as acetylation, methyl…”
BackgroundComparative Assessment in Young and Elderly Men of the Gonadotropin Response to Aromatase Inhibition
T’Sjoen, G. G., Giagulli, V. A., Delva, H., Crabbe, P., De Bacquer, D., & Kaufman, J.-M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0982 · Cited by 73 · cited 1×
“Furthermore, since the effects of both drugs were similar in young and elderly men, it can be hypothesized that an increased negative feedback by endogenous oestrogens is not instrumental in age-related decline of Leydig cell function in elderly men [13].”
BackgroundSelf-citationRosen, J., & Negro-Vilar, A. F. (2002) · PubMed · Cited by 71
GSK2881078, a SARM, Produces Dose-Dependent Increases in Lean Mass in Healthy Older Men and Women
Neil, D., Clark, R. V., Magee, M., Billiard, J., Chan, A., Xue, Z., & Russell, A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02644 · Cited by 68
He, Y., Yin, D., Perera, M. A., Kirkovsky, L. I., Stourman, N. V., Li, W., Dalton, J. T., & Miller, D. D. (2002) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(02)01335-1 · Cited by 67
Clark, R. V., Walker, A. C., Andrews, S. M., Turnbull, P., Wald, J. A., & Magee, M. H. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13316 · Cited by 67
Jones, A., Hwang, D.-J., Narayanan, R., Miller, D. D., & Dalton, J. T. (2010) · Endocrinology · doi:10.1210/en.2010-0150 · Cited by 66 · cited 1×
“From a pathophysiological point of view, the interest is focused on catabolic conditions, such as muscle atrophy as observed in sepsis, ageing, cancer, AIDS [53], and bone catabolism in osteoporosis; the effects of nonsteroidal SARM have been explored in castrated male Sprague Dawley rats and compared with glucocortic…”
BackgroundAlternatives to Testosterone Therapy: A Review
Lo, E. M., Rodriguez, K. M., Pastuszak, A. W., & Khera, M. (2018) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.09.004 · Cited by 64 · cited 2×
“On the contrary, both SERMs and AIs maintain the fertility, avoiding the block of spermatogenesis, as TRT does [7, 8].”
BackgroundYeap, B. B., Grossmann, M., McLachlan, R. I., Handelsman, D. J., Wittert, G. A., Conway, A. J., Stuckey, B. G., Lording, D. W., Allan, C. A., Zajac, J. D., et al. (2016) · Medical Journal of Australia · doi:10.5694/mja16.00448 · Cited by 61 · cited 1×
“, obesity, metabolic syndrome, diabetes mellitus, and so on) have been suggested [3, 4].”
BackgroundPredicting Biochemical Response to Clomiphene Citrate in Men with Hypogonadism
Mazzola, C. R., Katz, D. J., Loghmanieh, N., Nelson, C. J., & Mulhall, J. P. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12592 · Cited by 50 · cited 1×
“Indeed, a retrospective study indicated that a testicular volume <14 cc and LH levels >6UI/ml might be considered as the strong predictors of a good response to CC treatment [10], highlighting that all forms of primary hypogonadism and the secondary organic onesmight be unresponsive to that therapy [11].”
BackgroundAromatase Inhibition Reduces Insulin Sensitivity in Healthy Men
Gibb, F. W., Homer, N. Z. M., Faqehi, A. M. M., Upreti, R., Livingstone, D. E., McInnes, K. J., Andrew, R., & Walker, B. R. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4146 · Cited by 49 · cited 1×
“A normal/high T/E2 ratio has proven to be able to reduce insulin resistance by lowering insulin and glucose levels, without body composition changing in nonobese adult men [17], highlighting a direct and specific role of T in coregulating the insulin secretion and activity [18].”
BackgroundWheeler, K. M., Smith, R. P., Kumar, R. A., Setia, S., Costabile, R. A., & Kavoussi, P. K. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.068 · Cited by 47 · cited 1×
“However, AIs could determine a reduction in bone mineral density owing to their suppressive effect on serum oestrogens [26], whereas CC therapy caused a markedly lower incidence of secondary polycythaemia in comparison with TRT in hypogonadal men [27].”
ResultPelusi, C., Giagulli, V. A., Baccini, M., Fanelli, F., Mezzullo, M., Fazzini, A., Bianchi, N., Carbone, M. D., De Pergola, G., Mastroroberto, M., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0183369 · Cited by 45 · cited 1×
“In a recent double-blind placebo-controlled study, CC (25mg/day) improved fasting glycaemia, insulin levels, and homeostasis model assessment estimate of insulin-resistance (HOMAIR) in obese men with functional secondary hypogonadism, regardless of their glucose tolerance state (impaired glucose tolerance or type 2 di…”
BackgroundSelf-citationVarimo, T. J., Huopio, H., Kariola, L., Tenhola, S., Voutilainen, R., Toppari, J., Toiviainen‐Salo, S., Hämäläinen, E. K., Pulkkinen, M., Lääperi, M., et al. (2019) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30377-8 · Cited by 44
TENOVER, J. S., & BREMNER, W. J. (1991) · Journal of Andrology · doi:10.1002/j.1939-4640.1991.tb00265.x · Cited by 41 · cited 1×
“5mg/die) were able to raise plasma levels of LH and FSH, highlighting the key inhibiting role of oestrogens levels on gonadotropins secretion at the hypothalamus-pituitary level [12].”
BackgroundChandrapal, J. C., Nielson, S., Patel, D. P., Zhang, C., Presson, A. P., Brant, W. O., Myers, J. B., & Hotaling, J. M. (2016) · BJU International · doi:10.1111/bju.13546 · Cited by 38 · cited 1×
“At variance with these results, both a retrospective study evaluating 77 hypogonadal and infertile men treated with CC [23] and a double-blind placebo-controlled study involving 17 subjects did not show any improvement in sexual function during CC therapy [24].”
ResultLapauw, B., Ouwens, M., ′t Hart, L. M., Wuyts, B., Holst, J. J., T'Sjoen, G., Kaufman, J.-M., & Ruige, J. B. (2010) · Diabetes Care · doi:10.2337/dc10-0515 · Cited by 32 · cited 1×
“A normal/high T/E2 ratio has proven to be able to reduce insulin resistance by lowering insulin and glucose levels, without body composition changing in nonobese adult men [17], highlighting a direct and specific role of T in coregulating the insulin secretion and activity [18].”
BackgroundDevelopment of a selective androgen receptor modulator for transdermal use in hypogonadal patients
Krishnan, V., Patel, N. J., MacKrell, J. G., Sweetana, S. A., Bullock, H. A., Ma, Y. L., Waterhouse, T., Yaden, B. C., Henck, J. W., Zeng, Q., et al. (2018) · Andrology · doi:10.1111/andr.12479 · Cited by 23 · cited 1×
“With the aim to reduce the above negative effect on HDL levels that can allow to also use SARMs in elderly hypogonadal men, a recent transdermal SARM (LY305) has been proposed in the preclinical study [66].”
BackgroundRecent advances in the development of selective androgen receptor modulators
Zhang, X., Lanter, J. C., & Sui, Z. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902994397 · Cited by 22 · cited 1×
“-en, different classes of SARMs have been obtained, including propionamide, quinolinone, tetrahydroquinoline, bicyclic-hydantoin, pyrazoline, imidazolpyrazole, benzimidazole, and aniline [52].”
BackgroundMolecular Signaling in Spermatogenesis and Male Infertility
Santos, D. L., & Payan‐Carreira, R. (2019) · CRC Press eBooks · doi:10.1201/9780429244216 · Cited by 21
Liel, Y. (2016) · Endocrine Practice · doi:10.4158/ep161543.or · Cited by 14 · cited 1×
“Indeed, a retrospective study indicated that a testicular volume <14 cc and LH levels >6UI/ml might be considered as the strong predictors of a good response to CC treatment [10], highlighting that all forms of primary hypogonadism and the secondary organic onesmight be unresponsive to that therapy [11].”
Background
Cited by
Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
Ide, V., Vanderschueren, D., & Antonio, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010021 · Cited by 101
“However, they require a functional HPG axis and cannot be used in men with organic hypogonadism [47].”
BackgroundInfluentialShpakov, A. O. (2021) · Pharmaceuticals · doi:10.3390/ph14010042 · Cited by 91
Annual banned‐substance review: Analytical approaches in human sports drug testing 2019/2020
Thevis, M., Kuuranne, T., & Geyer, H. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2969 · Cited by 35
Xie, Y., Tian, Y., Zhang, Y., Zhang, Z., Chen, R., Li, M., Tang, J., Bian, J., Li, Z., & Xu, X. J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114119 · Cited by 33
Lisco, G., Giagulli, V. A., Tullio, A. D., Pergola, G. D., Guastamacchia, E., & Triggiani, V. (2020) · Geriatrics · doi:10.3390/geriatrics5040076 · Cited by 29
Self-citation
Metadata
- Authors
- Giagulli, V. A., Silvestrini, A., Bruno, C., Triggiani, V., Mordente, A., & Mancini, A.
- Affiliations
- University of Bari Aldo Moro (IT)
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Silvestrini, Andrea
- Mancini, Antonio
- ORCID
- Venue
- International Journal of Endocrinology
- Publisher
- Wiley
- Published
- 2020-01-21
- Volume
- 2020
- Pages
- 1-9
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- PMC
- PMC7201459
- OpenAlex
- W3001691037
- Cited by
- 14
- References
- 68
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 3
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- male hypogonadism, selective estrogen receptor modulators, selective androgen receptor modulators, aromatase inhibitors, testosterone replacement therapy, androgen receptor, hypothalamic-pituitary-testicular axis, obesity, chronic inflammatory diseases, gonadotropin secretion, anabolic effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.